Mitochondrial

SLU-PP-332

ERRγ Agonist · Exercise Mimetic Compound

SLU-PP-332 is a bleeding-edge synthetic ERRγ agonist hailed as the premier "exercise mimetic." Developed by pharmacological researchers to replicate the profound metabolic adaptations of intense endurance training entirely without physical exertion. It is aggressively utilized in extreme body recomposition protocols and sarcopenia reversal to force the biology of a marathon runner onto a sedentary metabolism - driving unparalleled fat oxidation and cardiovascular mitochondrial density.

Not FDA-approved - research chemical
Reviewed by CalcMyPeptide Editorial Team
Last updated: August 2026Evidence: Low1 peer-reviewed citation
Typical research dose
5-25 mg/day (oral)
Frequency
1× daily
Half-life
Short (small molecule)
Common vials
N/A (oral)
CAS
N/A (research compound)
Molecular weight
~350 Da

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

  • Metabolic / weight2/10

    Animal exercise-mimetic papers. Not a human trial. Not a peptide.

Compound card

Class
ERR pan-agonist small molecule (exercise-mimetic research; not a peptide)
Formula
Small molecule (not a peptide)
Status
Not FDA-approved · research use

How it works

SLU-PP-332 is a synthetic small molecule agonist of ERR (estrogen-related receptor) alpha and gamma nuclear receptors. It activates a transcriptional program that mimics intense aerobic exercise at the molecular level - specifically the fast-twitch to slow-twitch fiber type conversion and mitochondrial biogenesis that occur with endurance training.

ERR activation upregulates PPARGC1A (PGC-1α), the master regulator of mitochondrial biogenesis, and drives expression of slow-twitch muscle fiber genes (TNNI1, MYH7). In mouse studies, SLU-PP-332 significantly improved endurance capacity and metabolic rate, and prevented obesity on high-fat diet - mimicking the effects of exercise training without movement.

Source: PMID: 37279079

Background & History

SLU-PP-332 was developed at Saint Louis University (hence "SLU") by Thomas Burris and colleagues. Published in PNAS (2023), the compound activates ERRγ - a nuclear receptor highly expressed in metabolic tissues. The headline result: mice ran 70% longer and 45% farther than controls WITHOUT exercise training. This "exercise mimetic" effect attracted immediate interest in the longevity and performance communities. Unlike previous exercise mimetics (AICAR, GW501516), SLU-PP-332 targets a nuclear receptor rather than kinase signaling, providing a fundamentally different mechanism.

Research Use Cases

  • ✓Identity: ERRγ small molecule vs a peptide SKU (it is not a peptide)
  • ✓Mouse running data is not an endurance NDA
  • ✓Not an exercise replacement or sarcopenia protocol on this site

Dosing

PhaseDoseFrequencyNotes
Research (Preclinical Only)TBDNo established human protocolANIMAL DATA ONLY. No human trials or dosing protocols established. Extremely early research stage.

Administration

Route / form
Not established for human use
Timing
N/A
Empty stomach?
No - Food timing is not critical.

Timeline

Preclinical (animal)
Improved endurance, mitochondrial biogenesis, slow-twitch fiber conversion, fat loss without caloric restriction.

Who it is for

Exercise Mimetic / Endurance

Low

Strong preclinical data mimicking endurance exercise effects. Human data does not exist.

Safety & Considerations

ANIMAL DATA ONLY as of 2024. No human safety data exists. Extremely early-stage research compound. Not for human use outside of supervised research settings.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

  • No human dose.
  • This site will not treat mitochondrial disease from this page.

Verdict

SLU-PP-332 is an estrogen-related-receptor agonist research chemical. Exercise-mimetic headlines are mouse work. Not MOTS-c. Not a peptide.

Interactions & Contraindications

Pre-clinical compound - no established human interactions. Small molecule, not a peptide (oral bioavailability). Theoretical ERR family involvement in hormone-sensitive cancers - contraindicated in ER+ or hormone-sensitive malignancies. Monitor liver enzymes.

Synergies & Common Stacks

SLU-PP-332 (ERRγ → mitochondrial gene programs) + MOTS-c (AMPK → metabolic flexibility) target overlapping metabolic pathways through different mechanisms - potentially additive mitochondrial biogenesis.

ERR agonist mouse running data plus pineal-tetrapeptide folklore. Not a longevity stack and not an exercise replacement.

Frequently Asked Questions

Is SLU-PP-332 safe for humans?▼
No human safety data exists as of 2024. SLU-PP-332 has only been studied in mouse models. While the preclinical data is exciting, human use is premature and potentially unsafe without proper clinical trial data.

References

  1. Kumar N et al. “"ERR agonist SLU-PP-332 improves exercise capacity and metabolic health".” Journal of Pharmacology and Experimental Therapeutics (2023). PMID: 37344122
Recommended source10% OFF

Get SLU-PP-332 from our recommended source - independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.

Affiliate link · Full review